BR 2007
Alternative Names: BR-2007Latest Information Update: 23 Mar 2022
At a glance
- Originator Boryung Pharmaceutical
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 31 Jan 2022 Discontinued for Cancer in South Korea (Boryung Pharmaceuticals' pipeline, January 2022)
- 20 May 2020 Early research in Cancer in South Korea (unspecified route), prior to May 2020 (Boryung Pharmaceutical pipeline, May 2020)